Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 04

1278P - How do hospitalized patients with chronic liver disease, with and without hepatocellular carcinoma, die? End-of-life quality analysis

Date

10 Sep 2022

Session

Poster session 04

Topics

End-of-Life Care

Tumour Site

Hepatobiliary Cancers

Presenters

Ana Catarina Bravo

Citation

Annals of Oncology (2022) 33 (suppl_7): S581-S591. 10.1016/annonc/annonc1066

Authors

A.C. Bravo, C.N. Nascimento, B. Abreu, J. Revés, B. Morão, C. Frias-Gomes, M. Canhoto, L. Glória, C.A. Fidalgo

Author affiliations

  • Gastroenterology, Hospital Beatriz Ângelo, 2674-514 - Loures/PT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1278P

Background

Chronic liver disease (CLD) is a major cause of morbidity and mortality. However, they are poorly established metrics to assess the quality of end-of-life (EOL) care in this context. Offering better care to who is dying is an important mission of health professionals, but EOL interventions can be futile, prolong suffering and consume resources better allocated to other needs. We aimed to characterize and compare the EOL of patients with CLD, with and without hepatocellular carcinoma (HCC).

Methods

Retrospective cohort study including all patients who died with CLD between 2012-2021 in charge of Gastroenterology, in a tertiary hospital.

Results

72 patients, 89% male, with a mean age of 64±11 years, 68% Child-Pugh C and 50% with HCC. In the last 6 months of life, patients had a median of 2 (IQR 1-6) hospitalizations, and they were hospitalized a median of 21.5 (IQR 13.25-38.5) days, 15 (IQR 9.25-24.5) in the last month. Only 38% were referred to palliative care (PC), with a median of 5 (IQR 2-15) days between referral and death. 86% had prescribed do-not-resuscitate order, with a median of 3 (IQR 1-9) days between this and death. In 42%, endoscopic procedures were performed in the last hospitalization. In 58% and 17%, it was documented, in the clinical process, discussion of the prognosis with the family and the patient, respectively. There was a significant difference between patients with and without HCC in their referral to PC (53% vs 22%, p-value 0.007) and sharing the prognosis with the patient (31% vs 3%, p-value 0.002).

Conclusions

In this cohort, there was a late referral to PC in general, being lower in the group of patients without HCC. It is imperative to select and apply quality of death metrics in patients with CLD, with and without HCC, aiming to improve care, manage expectations and resources.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.